CoChat

Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis

Bernstein, D.I., Levy, A.L., Hampel, F.C., Baidoo, C.A., Cook, C.K., Philpot, E.E., Rickard, K.A. · 2004 · Clinical & Experimental Allergy
Cited by 88

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Summary: Background If monotherapy with an intranasal corticosteroid can alleviate both nasal and ocular symptoms of allergic rhinitis, treatment may be simplified and costs may be reduced. Objective The purpose of this study was to evaluate the efficacy of once‐daily fluticasone propionate (FP) aqueous nasal spray 200 μg compared with vehicle placebo and oral loratadine (LOR) 10 mg in reducing ocular symptoms associated with seasonal allergic rhinitis. Methods A total of 471 patients received vehicle placebo, LOR, or FP in this multi‐centre, double‐blind, double‐dummy, randomized study. Patients were12 years old with a history of seasonal allergic rhinitis and a positive skin test for a relevant allergen. During the baseline and treatment periods, patients rated the severity of eye itching, tearing, and redness via visual analogue scales that ranged from 0 (no symptoms) to 100 (most severe symptoms). The three ocular ratings were added to derive the total ocular symptom score (TOSS). Patients with a TOSS120 on at least 4 of the 7 days before the randomization visit were enrolled. The primary outcome was the difference between FP and vehicle placebo in the mean change from baseline in the reflective TOSS overall (averaged over the 28‐day treatment period). A difference between FP and vehicle placebo of 25.5 was considered clinically significant. Results The overall mean change from baseline in the TOSS was significantly greater in the FP group compared with vehicle placebo (clinically significant difference of 28.8; P<0.001) and compared with LOR (difference of 16.2; P=0.028). Overall mean (SEM) changes were −59.9 (5.4) for the placebo group, −72.5 (5.4) for the LOR group, and −88.7 (5.3) for the FP group. The FP treatment group also showed significantly greater overall mean changes in ocular itching, tearing, and redness compared with vehicle placebo (P<0.001) and compared with LOR (P 0.045). Conclusion Patients treated with intranasal FP had clinically and statistically significant decreases in ocular symptom scores compared with vehicle placebo. Data also suggest that FP reduced ocular symptoms more than or comparable with oral LOR. Patients experiencing ocular symptoms associated with allergic rhinitis may benefit from monotherapy with intranasal FP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2004.01952.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 88

Metadata

Authors
Bernstein, D. I., Levy, A. L., Hampel, F. C., Baidoo, C. A., Cook, C. K., Philpot, E. E., & Rickard, K. A.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2004-06
Volume
34
Issue
6
Pages
952-957
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W2025255009
Cited by
88
References
1
FWCI
1.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. https://app.cochat.ai/papers/10.1111/j.1365-2222.2004.01952.x
The paper
Bernstein, D. I., Levy, A. L., Hampel, F. C., Baidoo, C. A., Cook, C. K., Philpot, E. E., & Rickard, K. A. (2004). Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2004.01952.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.